Company intelligence / Profile preview

Uncommon

Cambridge, Cambridgeshire, United Kingdomuncommonschools.org ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Uncommon has developed a proprietary process to produce cultivated pork products—such as bacon and pork belly—using porcine induced pluripotent stem cells. The company claims its technology can reduce CO₂ emissions by 80% per pound of pork compared to conventional methods. It does not use genetic engineering and aims for price parity with conventional pork. As of June 2023, Uncommon had moved into a new HQ with a pilot plant and closed a $30M Series A funding round.

Modalities: Cell-based food production (cultivated/cultured meat using stem cells)
Industry: Non-Drug Biotech

Partnerships

Apollo ProjectsBalderton CapitalLowercarbon Capital

Beyond the preview

Go deeper on Uncommon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uncommon.

Explore the full profile